French haemophiliac wins right to sue:
This article was originally published in Clinica
Executive Summary
A French haemophiliac who contracted HIV from contaminated blood has been granted the right to file suit against the country's blood transfusion service. The European Commission on Human Rights ruled that Daniel Bellet had been denied a fair public hearing. Mr Bellet was diagnosed with the virus in 1983 and nine years later awarded Fr 1.3 million ($260,000) from the transfusion service's indemnity fund. He was also awarded Fr 3 million by the national blood transfusion foundation, but had the latter decision overturned by the Paris Court of Appeal, which claimed he had already been fully indemnified. The Commission ruled under French law, such an award does not preclude legal action, reports Le Quotidien du Medecin.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.